Skip Navigation



Annals of Oncology Advance Access published online on July 23, 2009
Annals of Oncology, doi:10.1093/annonc/mdp293
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
21/2/238    most recent
mdp293v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Alkner, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Alkner, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

AIB1 is a predictive factor for tamoxifen response in premenopausal women

S. Alkner1, P.-O. Bendahl1, D. Grabau2, K. Lövgren1, O. Stål3, L. Rydén4, M. Fernö1,* and on behalf of the South Swedish and South-East Swedish Breast Cancer Groups

1 Department of Oncology, Clinical Sciences, Lund University
2 Department of Pathology, Clinical Sciences, Lund University
3 Department of Oncology, Clinical and Experimental Medicine, Linköping University
4 Department of Surgery, Clinical Sciences, Lund University, Sweden

* Correspondence to: Prof. M. Fernö, Department of Oncology, Clinical Sciences, Barngatan 2B:1, Lund University Hospital, SE 221 85 Lund, Sweden. Tel: +46-46177565; Fax: +46-46147327; E-mail: Marten.Ferno{at}med.lu.se

Background: Clinical trials implicate the estrogen receptor (ER) coactivator amplified in breast cancer 1 (AIB1) to be a prognostic and a treatment-predictive factor, although results are not unanimous. We have further investigated this using a controlled randomised trial of tamoxifen versus control.

Materials and methods: A total of 564 premenopausal women were entered into a randomised study independent of ER status. Using a tissue microarray, AIB1 and ER were analysed by immunohistochemistry.

Results: AIB1 scores were obtained from 349 women. High AIB1 correlated to factors of worse prognosis (human epidermal growth factor receptor 2, Nottingham histological grade 3, and lymph node metastases) and to ER negativity. In the control arm, high AIB1 was a negative prognostic factor for recurrence-free survival (RFS) (P = 0.02). However, ER-positive patients with high AIB1 responded significantly to tamoxifen treatment (P = 0.002), increasing RFS to the same level as for systemically untreated patients with low AIB1. Although ER-positive patients with low AIB1 had a better RFS from the beginning, this was not further improved by tamoxifen (P = 0.8).

Conclusions: In the control group, high AIB1 was a negative prognostic factor. However, ER-positive patients with high AIB1 responded significantly to tamoxifen. This implicates high AIB1 to be an independent predictive factor of improved response to tamoxifen and not, as has previously been discussed, a factor predicting tamoxifen resistance.

amplified in breast cancer 1, breast cancer, coactivator, estrogen receptor, prognosis, tamoxifen

Received for publication February 14, 2009. Revision received April 21, 2009. Accepted for publication April 21, 2009.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.